Murphy, Middleton, Hinkle & Parker, Inc. Crispr Therapeutics Ag Transaction History
Murphy, Middleton, Hinkle & Parker, Inc.
- $393 Million
- Q4 2025
A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 906 shares of CRSP stock, worth $50,119. This represents 0.01% of its overall portfolio holdings.
Number of Shares
906Holding current value
$50,119% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
547Shares Held
67.6MCall Options Held
3.5MPut Options Held
3.08M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl9.79MShares$541 Million4.45% of portfolio
-
Capital International Investors Los Angeles, CA5.65MShares$313 Million0.06% of portfolio
-
Orbis Allan Gray LTD Hamilton, D04.98MShares$276 Million1.8% of portfolio
-
State Street Corp Boston, MA4.01MShares$222 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.28MShares$182 Million0.13% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.32B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....